enomeFrontier is an innovation-driven therapeutic company, focusing on the development of next-generation gene therapies. Striving to reach the pinnacle in the field of gene therapy, we leveraged four proprietary virus-free gene and cell engineering platforms and successfully created a robust cell-engineering Quantum Engine™ system that can potentially cure a wide range of diseases, including cancer.
Chimeric antigen receptor T (CAR-T) and T cell receptor T (TCR-T) are genetically reprogrammed T cells that are used for adoptive immune cell therapy. CAR-T cells recognize cell surface antigens, whereas TCR-T cells recognize endogenous antigens presented in the context of human leukocyte antigen (HLA). Currently, several CAR-T and TCR-T cell products for cancer treatment are under development using GenomeFrontier’s Quantum Engine™.